Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Key 2023 readouts for high-value medicines on track
Key assets* with submission enabling readouts in 2023
KisqaliⓇ
Ph3 NATALEE trial in
adjuvant breast cancer
testing broad patient
population (anatomical
stage II and III¹), with
final analysis expected
in H2 2023
Primary
endpoint
met at
interim
analysis
PluvictoⓇ
PSMAfore trial in mCRPC
(post-ARDT, pre-taxane) positive
readout; detailed data presentation
planned in H2 2023
FDA regulatory submission
planned in H2 2023
Iptacopan
APPOINT-PNH trial in
treatment-naive patients
positive readout; detailed
data presentation in 2023
PNH FDA filing
planned in H1 2023
APPLAUSE-IgAN Ph3 readout²
planned in H2 2023
APPEAR-C3G Ph3 readout
planned in H2 2023
*Unprobabilized peak sales of all asset indications in late-stage development: > USD 1bn
> USD 2bn
> USD 3bn
mCRPC metastatic castration resistant prostate cancer. ARDT-androgen receptor directed therapy. 1. Based on AJCC prognostic staging.
2. 9 months analysis potentially supporting US Subpart H filing.
5 Investor Relations | Q1 2023 Results
INNOVATION
Data at
EBMT
✓ NOVARTIS | Reimagining MedicineView entire presentation